Richter J.E., Kahrilas P.J., Johanson J. et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: A randomized controlled trial // Amer. J. Gastroenterol. - 2001. - Vol. 96. - P. 656-665.

Rohss K., Claar-Nilsson C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg // Gastroenterol. - 2000.-Vol. 118.-A20.

Rohss K., Lind T., Wilder-Smith C. Esomeprazole (40 mg) provides more effective intragastric acid control than lansoprazole (30 mg), omeprazole (40 mg), pantoprazole (40 mg), rabeprazole (40 mg) in patients with gastro-oesophageal reflux symptoms. Eur. J. Clin. Pharmacol. (2004), 60: 531-539.

Rohss K., Lundin C, Rydholm H., Nyman L. Es-omeprazole 40 mg provides more effective acid control than omeprazole 40 mg // Gut. - 2000. - Vol. 47 (Suppl. III). - A63.

Rohss K., Wilder-Smith C.H., Claar-Nilsson C. et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors // J. Gastroenterol. Hepatol. - 2002. - Vol. 17 (Suppl.). - A228.

Rollhausen C. NSAIDs and upper gastrointestinal bleeding. Endoscopy, 2003; 35: 372-3.

Rollhauser C, Fleischer D. Ulcers and nonvariceal bleeding. Endoscopy, 1999,31 (1), p. 17-25.

R hss K, Bondarov P, Lundin C, Nilsson-Pieschi C, Nyman L, Niazi M. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects [Abstract]. Gastroenterology 2003; 122 (4Suppl.):A-231.

Schonekas H. et al. Gastroenterology 1999; 116, 4 (Part 2):A305.(16)

Sneider H., Van Rensburg C, Schmidt S. et al. Esomeprazole 40 mg administred intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion 2004; 70: 250 - 256.

Sung JJ, etal. Aliment PharmacolTher2008;27:666-77.

Sung J J, etal. Scand J Gastroenterol 2008;43(Suppl 244):Or19

Talley N., Vanables T., Green J. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopynegative GERD: A placebo-controlled trial of on-demand therapy for 6 months // Gastroenterol. - 2000. - Vol. 118. - A658.

Thomson A.B.R., Claar-Nilsson C, Hasselgren G. et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration // Gut. - 2000. - Vol. 47 (Suppl. III). - A63.

Tulassay Z., Kryszwski A., Dite P. et al. 7-day treatment with esomeprazole triple therapy eradicates Helicobacter pylori and heales patients with duodenal ulcer disease // Gastroenterol. - 2000. - Vol. 118. - A502.

Tulley N. J., Lauritsen K., Tunturi-Hihnala H. et al. Es-omeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of «on-de-mand» therapy for 6 months // Aliment. Pharmacol. Ther. - 2001. - Vol. 15. - P. 347-354.

Tunturi-Hihnala H. et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of on-demand therapy for 6 months // Aliment. Pharmacol. Ther. - 2001. - Vol. 15. -P. 347-354.

Vakil N.B., Shaker R., Johnson D.A. et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-months, randomized, double-blind, placebo-controlled study of efficacy and safety // Aliment. Pharmacol. Ther. - 2001. - Vol. 15. - P. 927-935.

Walt RP, Cottrell J, Mann SG, Freemantle NP, Lang-man MJS. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992;340:1058-1062.

Walt RP, Reynolds JR, Langman MJ, Smart HL, Kitchingman G, Somerville KW, Hawkey CJ. Intravenous omeprazole rapidly raises intragastric pH. Lancet 1992;340:1062-1068.

Van Pinxtern B., Numans M.E., Bonis A., Lan S. Short-term treatment with proton pump inhibitors, H2-receptor antagonist and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease // Cochrane Database Syst. Rev. - 2000. - 2.

Wilder-Smith C, Bondarov P., Lindgren M. et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized

clinical studies. Eur. Journal of Gastroenterol. And Hepatol. 2005,17:191-197.

Wilder-Smith C, Rohss K., Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg // J . Gastroenterol. Hepatol. - 2002. - Vol. 17 (Suppl.). -A7845.

Wilder-Smith C.H., Claar-Nilsson C, Hasselgren G., Rohss K. Esomeprazole 40 mg provides factor and effective acid control than rabeprazole 20 mg in patients with symptoms of GERD // J. Gastroenterol. Hepatol. - 2002. - Vol. 17 (Sup-pl.).-A612.

Wilder-Smith C.H., Rohss K., Lundin C. Esomepra-zole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg // Gastroenterol. - 2000. - Vol. 118. - A22.

ZhonglinY. etal. J. Gastroenterol. Hepatol. 2002; 17 (Suppl): A257.(17).

Мы благодарны автору и издательствам, которые не противодействует, а способствует образованию медицинских работников.
В случае нарушения авторских прав, пожалуйста, напиши нам и материалы будут незамедлительно удалены!